Ldlr - low density lipoprotein receptor Gene

Also Known as Hlb301

Species: Mus musculus

Gene Type: protein coding
Gene ID: 16835

Summary

Enables several functions, including amyloid-beta binding activity; low-density lipoprotein particle binding activity; and low-density lipoprotein particle receptor activity. Involved in several processes, including lipid transport; regulation of inflammatory response; and regulation of lipid metabolic process. Acts upstream of or within several processes, including Cholesterol homeostasis; lipoprotein catabolic process; and low-density lipoprotein particle clearance. Located in several cellular components, including basolateral plasma membrane; endosome; and lysosome. Is expressed in several structures, including alimentary system; genitourinary system; musculoskeletal system; paravertebral ganglion; and sensory organ. Used to study familial hypercholesterolemia and fatty liver disease. Human ortholog(s) of this gene implicated in Alzheimer's disease; arteriosclerosis; familial hypercholesterolemia; hepatitis C; and migraine without aura. Orthologous to human LDLR (low density lipoprotein receptor). [provided by Alliance of Genome Resources, Apr 2022]

Ldlr Products (3)

mRNA Protein Name
NM_001252658.1 NP_001239587.1 low-density lipoprotein receptor isoform 2 precursor
NM_001252659.1 NP_001239588.1 low-density lipoprotein receptor isoform 3 presursor precursor
NM_010700.3 NP_034830.2 low-density lipoprotein receptor isoform 1 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables amyloid-beta binding IPI
IPI: Inferred from physical interaction
22383525 MGI
enables low-density lipoprotein particle binding IDA
IDA: Inferred from direct assay
7848292 MGI
enables low-density lipoprotein particle receptor activity IDA
IDA: Inferred from direct assay
12072432 MGI
enables low-density lipoprotein particle receptor activity IMP
IMP: Inferred from mutant phenotype
17148552 MGI
enables protein binding IPI
IPI: Inferred from physical interaction
12169628 MGI
enables very-low-density lipoprotein particle receptor activity IDA
IDA: Inferred from direct assay
16166565 MGI
Biological Process GO Annotation Evidence References Source
involved in amyloid-beta clearance IGI
IGI: Inferred from genetic interaction
20005821 MGI
involved in amyloid-beta clearance by cellular catabolic process IDA
IDA: Inferred from direct assay
22383525 MGI
involved in artery morphogenesis IMP
IMP: Inferred from mutant phenotype
22927332 MGI
involved in cellular response to fatty acid IGI
IGI: Inferred from genetic interaction
24255059 MGI
acts upstream of or within cholesterol homeostasis IGI
IGI: Inferred from genetic interaction
11120757 MGI
involved in cholesterol homeostasis IGI
IGI: Inferred from genetic interaction
25524771 MGI
acts upstream of or within cholesterol homeostasis IMP
IMP: Inferred from mutant phenotype
9788969 MGI
involved in cholesterol import IMP
IMP: Inferred from mutant phenotype
18175806 MGI
acts upstream of or within cholesterol metabolic process IMP
IMP: Inferred from mutant phenotype
17071966 MGI
acts upstream of or within cholesterol transport IMP
IMP: Inferred from mutant phenotype
17148552 MGI
acts upstream of or within establishment of localization in cell IMP
IMP: Inferred from mutant phenotype
17148552 MGI
involved in high-density lipoprotein particle clearance IGI
IGI: Inferred from genetic interaction
25524771 MGI
acts upstream of or within lipid metabolic process IGI
IGI: Inferred from genetic interaction
11120757 MGI
acts upstream of or within lipoprotein catabolic process IDA
IDA: Inferred from direct assay
15741654 MGI
acts upstream of or within lipoprotein catabolic process IMP
IMP: Inferred from mutant phenotype
9788969 MGI
acts upstream of or within lipoprotein metabolic process IGI
IGI: Inferred from genetic interaction
11120757 MGI
involved in long-term memory IGI
IGI: Inferred from genetic interaction
24412220 MGI
acts upstream of or within low-density lipoprotein particle clearance IDA
IDA: Inferred from direct assay
26965651 MGI
involved in low-density lipoprotein particle clearance IMP
IMP: Inferred from mutant phenotype
18175806 MGI
involved in negative regulation of amyloid fibril formation IGI
IGI: Inferred from genetic interaction
20005821 MGI
involved in negative regulation of astrocyte activation IGI
IGI: Inferred from genetic interaction
20005821 MGI
involved in negative regulation of gene expression IMP
IMP: Inferred from mutant phenotype
24255059 MGI
involved in negative regulation of microglial cell activation IGI
IGI: Inferred from genetic interaction
20005821 MGI
involved in negative regulation of protein metabolic process IDA
IDA: Inferred from direct assay
22383525 MGI
involved in phagocytosis IDA
IDA: Inferred from direct assay
22383525 MGI
involved in phospholipid transport IMP
IMP: Inferred from mutant phenotype
18175806 MGI
involved in plasma lipoprotein particle clearance IDA
IDA: Inferred from direct assay
22383525 MGI
involved in positive regulation of gene expression IGI
IGI: Inferred from genetic interaction
24255059 MGI
involved in positive regulation of gene expression IMP
IMP: Inferred from mutant phenotype
24255059 MGI
involved in positive regulation of inflammatory response IGI
IGI: Inferred from genetic interaction
24255059 MGI
involved in positive regulation of lysosomal protein catabolic process IDA
IDA: Inferred from direct assay
22383525 MGI
involved in positive regulation of triglyceride biosynthetic process IMP
IMP: Inferred from mutant phenotype
18175806 MGI
involved in receptor-mediated endocytosis IDA
IDA: Inferred from direct assay
20005821 MGI
involved in regulation of cholesterol metabolic process IGI
IGI: Inferred from genetic interaction
24412220 MGI
involved in regulation of phosphatidylcholine catabolic process IMP
IMP: Inferred from mutant phenotype
18175806 MGI
involved in regulation of protein metabolic process IGI
IGI: Inferred from genetic interaction
24412220 MGI
involved in response to caloric restriction IGI
IGI: Inferred from genetic interaction
24412220 MGI
Cellular Component GO Annotation Evidence References Source
located in apical part of cell IDA
IDA: Inferred from direct assay
22848640 MGI
located in basolateral plasma membrane IDA
IDA: Inferred from direct assay
22848640 MGI
located in cell surface IDA
IDA: Inferred from direct assay
22848640 MGI
located in early endosome IDA
IDA: Inferred from direct assay
11092755 MGI
located in endosome IDA
IDA: Inferred from direct assay
12746448 MGI
located in late endosome IDA
IDA: Inferred from direct assay
11092755 MGI
located in lysosome IDA
IDA: Inferred from direct assay
11092755 MGI
located in plasma membrane IDA
IDA: Inferred from direct assay
20005821 MGI
located in somatodendritic compartment IDA
IDA: Inferred from direct assay
18341993 MGI
located in sorting endosome IDA
IDA: Inferred from direct assay
11092755 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

low-density lipoprotein receptor

  • LDL receptor

Recombinant Ldlr Proteins

Cat. No. Product Name Accession Purity
HY-P73272 LDLR Protein, Mouse (HEK293, His) P35951 (A22-R790) ≥ 90%, as determined by reducing SDS-PAGE.
HY-P73838 LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) P35951/NP_034830.2 (A22-R790, A23V, C27G) ≥ 90%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-14668 Lomitapide mesylate Inhibitor 99.68% Yes
HY-B0374A Moxonidine hydrochloride 99.83% Unkown
HY-B0374 Moxonidine 99.72% Unkown

Clinical Phase

Bioactive Molecules (8)
Cat. No. Product Name Effect
Purity Phase
HY-152857 Muvalaplin Inhibitor 99.96% Phase 3
HY-P4073 ANG1005 98.83% Phase 3
HY-18778 Obicetrapib Inhibitor 99.93% Phase 3
HY-124560 Lifibrol 99.69% Phase 3
HY-109567 Gemcabene Inhibitor 99.91% Phase 2
HY-N0466 Rebaudioside A Activator 98.0% Phase 1
HY-116175 BIBB 515 99.56% Phase 1
HY-172661 Kylo-0603 Inhibitor / Phase 1
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P99793 Orticumab Inhibitor ≥99.0% Phase 2

Pre-clinical Phase

Bioactive Molecules (64)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-NP013 Oxidized low density lipoprotein (mouse) 98.00% Unkown
HY-P2341 Angiopep-2 hydrochloride 99.61% Unkown
HY-145001 20-HC-Me-Pyrrolidine Inhibitor 99.69% Unkown
HY-W007347 1,2-Cyclohexanedione 98.68% Unkown
HY-W015600 2-Acetamidophenol Inhibitor 99.73% Unkown
HY-101354 R-IMPP Activator 99.93% Unkown
HY-101529 Imanixil 99.29% Unkown
HY-N0627 Kaempferol-7-O-β-D-glucopyranoside 99.79% Unkown
HY-N0430A Coptisine Sulfate 99.37% Unkown
HY-158424 LSN3353871 Inhibitor 99.62% Unkown
HY-W018587 TBPH 95.0% Unkown
HY-P10502A L57 acetate 99.01% Unkown
HY-125544 LY 295427 Modulator 98.0% Unkown
HY-142026 Vitisin A Inhibitor 97% Unkown
HY-W015600S 2-Acetamidophenol-d3 99.48% Unkown
HY-120651 LDL-IN-2 Inhibitor 99.0% Unkown
HY-P10697A VH4127 TFA Modulator / Unkown
HY-P10502 L57 99.44% Unkown
HY-101812 Terbufibrol 98.39% Unkown
HY-W423578 LDLR regulator-1 Modulator 99.89% Unkown
HY-181997 LDLRAP1-IN-1 Inhibitor 98.08% Unkown
HY-109567A Gemcabene calcium Inhibitor 98.0% Yes
HY-A0127 Etofibrate Activator 99.80% Unkown
HY-N0430 Coptisine / Unkown
HY-130587 Sultosilic acid piperazine salt / Unkown
HY-100144 Pirozadil 98.31% Unkown
HY-P11452A (KKEEE)3K acetate 98.13% Unkown
HY-138089 17β-Hydroxy exemestane Inhibitor 98.21% Unkown
HY-159595 PCSK9-IN-29 Inducer 99.44% Unkown
HY-178335 SGC-CK1γ-1 Inhibitor 99.33% Unkown
HY-U00054 LDL-IN-3 Inhibitor / Unkown
HY-N15706 Luteolin-7-O-β-D-glucuronide methyl ester / Unkown
HY-P10911 IETP2 Ligand / Unkown
HY-105961 F 2833 Inhibitor / Unkown
HY-P10697B H-PEG6-VH4127-NH2 / Unkown
HY-167873 Habenariol Inhibitor / Unkown
HY-113288 Campestanol Inhibitor 99.0% Unkown
HY-P10698 VH-N412 / Unkown
HY-115914 Lipid-lowering agent-1 / Unkown
HY-P10697 VH4127 Modulator / Unkown
HY-P11771 KS-487 / Unkown
HY-177291 LAB687 Inhibitor / Unkown
HY-179459 SJ-300 Inhibitor / Unkown
HY-B0374AS Moxonidine-13C,d3 hydrochloride / Unkown
HY-161941 MeIm / Unkown
HY-18778A Obicetrapib sodium Inhibitor / Unkown
HY-172699 DSPE-PEG2000-ANG / Unkown
HY-P11413 PAI-1 / Unkown
HY-18778B Obicetrapib potassium Inhibitor / Unkown
HY-P11452 (KKEEE)3K / Unkown
HY-126551 Butenoyl-PAF / Unkown
HY-B0374S1 Moxonidine-d7 / Unkown
HY-147279 Milpocitide / Unkown
HY-P11071 PCSK9 Inhibitor, EGF-A Degrader / Unkown
HY-167870 Piceatannol 4'-O-glucoside Inhibitor / Unkown
HY-176274 FASN/SCD-IN-1 Inhibitor / Unkown
HY-187677 PCSK9-IN-36 Inhibitor / Unkown
HY-161938 BRD8518 / Unkown
HY-165512 Nicanartine Inhibitor 99.36% Unkown
HY-123260 S12340 Inhibitor / Unkown
HY-B0374S2 Moxonidine-d3 / Unkown
HY-18778C Obicetrapib hemicalcium Activator / Unkown
HY-B0374S Moxonidine-d4 / Unkown
HY-28911 2-Hydroxyacetaldehyde Modulator / Unkown
Inhibitory Antibodies (4)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990202 Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) Inhibitor 98.10% Unkown
HY-P99505 Ziltivekimab 99.75% Unkown
HY-P990143 Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) Inhibitor 95.00% Unkown
HY-P990480 Anti-oxLDL Antibody 96.99% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Ldlr NCBI NCBI:3949